Non-alcoholic fatty liver disease (NAFLD) is a pressing global health concern that is associated with metabolic syndrome and obesity. On the basis of the insights provided by Jiang et al, this editorial presents an exploration of the potent
Tag: Non-alcoholic fatty liver disease
Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant health challenge, characterized by its widespread prevalence, intricate natural progression and multifaceted pathogenesis. Although NAFLD initially presents as benign fa
Genetic variation with MASLD reveals subtypes and potential therapeutic avenues
A study reveals genetic subtypes, biomarkers, gene and pathway targets for the development of new treatments for this liver disease
Potential New Targets Identified in Advanced Non-Alcoholic Fatty Liver Disease
Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD). The research was led by investigators at the Icahn School of Medicine at Mount Sinai. Utilizing these innovative methods, the investigators discovered a network of cell-to-cell communication driving scarring as liver disease advances. The findings, published online on January 4 in Science Translational Medicine, could lead to new treatments.
Study: First-Degree Relatives of Patients with NAFLD at Risk of Liver Disease
New study identifies that first-degree relatives of patients with nonalcoholic fatty liver disease with advanced fibrosis (scarring of the liver) are at a 15% risk of developing the condition.
Lactating Mice Pass along Common Antimicrobial to Pups, Initiating Liver Damage
In mouse studies, UC San Diego researchers report that lactating mothers expose their feeding pups to triclosan, an antimicrobial commonly used in consumer products, resulting in early signs of liver damage.
Study: Liver Disease Linked to Higher Risk of Dementia
People who have non-alcoholic fatty liver disease, a buildup of fat cells in the liver, may have a higher risk of dementia, according to a new study published in the July 13, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology. Researchers also found that people with this form of liver disease who also have heart disease or who have had a stroke may have an even higher risk of dementia.
Pediatric Liver Disease Increases Risk of Developing Type 2 Diabetes
UC San Diego researchers describe connection between pediatric liver disease and increased risk of developing type 2 diabetes. Both rates are rising in children.
Liver Cancer Tumors Appear to Be Resistant to Immunotherapy in Patients With Underlying Non-alcoholic Steatohepatitis (NASH)
Immunotherapy is not only significantly less effective in liver cancer patients who previously had a liver disease called non-alcoholic steatohepatitis (NASH), but actually appears to fuel tumor growth, according to a Mount Sinai study published in Nature in March. NASH affects as many as 40 million people worldwide and is associated with obesity and diabetes.